Characterisation and Clinical Significance of FLT3-ITD and non-ITD in Acute Myeloid Leukaemia Patients in Kelantan, Northeast Peninsular Malaysia
Authors:
- Muhammad Farid JohanMJMuhammad Farid Johan
- Hamid Ali Nagi Al-JamalHamid Ali Nagi Al-Jamal
- Azlan HusinAHAzlan Husin
- Abdul Rahim HusseinAHAbdul Rahim Hussein
- Rosline HassanRHRosline Hassan
Open Access
- 13 July 2015
- journal article
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 16 (12) , 4869-4872
Abstract
Mutations of the FMS-like tyrosine kinase-3 (FLT3) receptor gene may promote proliferation via activation of multiple signaling pathways. FLT3-internal tandem duplication (FLT3-ITD) is the most common gene alteration found in patients diagnosed with acute myeloid leukaemia (AML) and has been associated with poor prognosis. We performed mutational analysis of exons 14-15 and 20 of the FLT3 gene in 54 AML patients using PCR-CSGE (conformational sensitive gel electrophoresis) followed by sequencing analysis to characterise FLT3 mutations in adult patients diagnosed with AML at Hospital USM, Kelantan, Northeast Peninsular Malaysia. FLT3 exon 14-15 mutations were identified in 7 of 54 patients (13%) whereas no mutation was found in FLT3 exon 20. Six ITDs and one non-ITD mutation were found in exon 14 of the juxtamembrane (JM) domain of FLT3. FLT3-ITD mutations were associated with a significantly higher blast percentage (p-value=0.008) and white blood cell count (p-value=0.023) but there was no significant difference in median overall survival time for FLT3-ITD+/FLT3-ITD- within 2 years (p-value=0.374). The incidence of FLT3-ITD in AML patients in this particular region of Malaysia is low compared to the Western world and has a significant association with WBC and blast percentage.Keywords
This publication has 18 references indexed in Scilit:
- Independent prognostic variables in acute myeloid leukaemiaBlood Reviews, 2011
- FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyBlood, 2010
- Genetic Tests To Evaluate Prognosis and Predict Therapeutic Response in Acute Myeloid LeukemiaThe Journal of Molecular Diagnostics, 2010
- Analysis ofFLT3-ITD andFLT3-Asp835 Mutations inde novoAcute Myeloid Leukemia: Evaluation of Incidence, Distribution Pattern, Correlation with Cytogenetics and Characterization of Internal Tandem Duplication from Indian PopulationCancer Investigation, 2009
- Structural and numerical variation of FLT3/ITD in pediatric AMLBlood, 2008
- The role of FLT3 in haematopoietic malignanciesNature Reviews Cancer, 2003
- FLT3-TKD mutation in childhood acute myeloid leukemiaLeukemia, 2003
- Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group UlmBlood, 2002
- Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domainOncogene, 2002
- Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignanciesBlood, 2001